Cipla Ltd's Q4FY25 Quarter Results
- 3d ago
Result Summary
- Cipla Ltd reported a 12.1% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 9.2%.
- Its expenses for the quarter were down by 4.2% QoQ and up 4.2% YoY.
- The net profit decreased 40.8% QoQ and increased 78.7% YoY.
- The earnings per share (EPS) of Cipla Ltd stood at 11.6 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 6412.57 | 7294.58 | 5873.93 | -12.1% | 9.2% |
Total Expenses | 5153.31 | 5378.49 | 4946.14 | -4.2% | 4.2% |
Profit Before Tax | 1259.26 | 1916.09 | 745.37 | -34.3% | 68.9% |
Tax | 324.86 | 332.37 | 222.25 | -2.3% | 46.2% |
Profit After Tax | 931.87 | 1574.59 | 521.51 | -40.8% | 78.7% |
Earnings Per Share | 11.60 | 0.00 | 6.50 | - | 78.5% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Cipla Ltd is a prominent pharmaceutical company headquartered in India, known for its extensive range of healthcare products, including generic drugs, active pharmaceutical ingredients (APIs), and over-the-counter (OTC) products. The company operates in the pharmaceutical industry, focusing on therapeutic areas such as respiratory, anti-infective, and cardiovascular segments, serving both domestic and international markets. Cipla has been actively involved in research and development, striving for innovation in its product offerings. The company has a significant global presence, exporting to over 80 countries, with manufacturing facilities strategically located in various regions. Any recent major developments specific to Cipla Ltd are not available within the provided data.
Revenue
In Q4FY25, Cipla Ltd reported a total income of ₹6412.57 crores, marking a decrease of 12.1% from the previous quarter Q3FY25, which recorded an income of ₹7294.58 crores. However, when compared to the same quarter in the previous fiscal year, Q4FY24, the total income increased by 9.2% from ₹5873.93 crores. This reflects a year-over-year growth while experiencing a quarter-over-quarter decline in revenue. These fluctuations in revenue indicate changes in the company's sales performance over the specified periods. The financial data highlights the company's ability to sustain year-over-year growth despite the quarterly decline.
Profitability
Cipla Ltd's profitability metrics for Q4FY25 show that the company achieved a profit before tax of ₹1259.26 crores, which represents a decrease of 34.3% from the previous quarter, Q3FY25, where the profit before tax was ₹1916.09 crores. Compared to Q4FY24, the profit before tax increased by 68.9% from ₹745.37 crores. The tax expense for Q4FY25 was ₹324.86 crores, slightly lower than the previous quarter's tax of ₹332.37 crores, exhibiting a 2.3% decrease quarter-over-quarter and a 46.2% increase year-over-year from Q4FY24's tax expense of ₹222.25 crores. The profit after tax for Q4FY25 stood at ₹931.87 crores, a decrease of 40.8% from Q3FY25 but an increase of 78.7% from Q4FY24's figure of ₹521.51 crores. Earnings per share for Q4FY25 were ₹11.60, showing a significant year-over-year increase of 78.5% compared to ₹6.50 in Q4FY24.
Operating Metrics
The analysis of Cipla Ltd's operating metrics indicates that total expenses for Q4FY25 were ₹5153.31 crores, which is a 4.2% decrease from Q3FY25's total expenses of ₹5378.49 crores. Year-over-year, the total expenses increased by 4.2% from Q4FY24's expenses of ₹4946.14 crores. These operating figures provide insight into the company's cost management strategies across different quarters. The data indicates a reduction in expenses compared to the previous quarter and an increase over the same quarter in the previous year. The fluctuation in expenses impacts the overall profitability and financial health of the company.
